A PHASE I/IB SINGLE ARM STUDY OF TWO FRACTION SBRT WITH DOMINANT LESION SIB FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER
Brief description of study
This study wants to find out if a new way of treating prostate cancer is safe and possible. They will use a special kind of radiation, SBRT (Stereotactic Body Radiation Therapy), given in only two doses (2 fractions), based on how the cancer looks on an MRI and how it's classified genetically. They will focus on men who are 18 or older and have prostate cancer that has been confirmed with a biopsy. The goal is to see if this treatment will work for them with minimal side effects.
Clinical Study Identifier: s22-01306
Principal Investigator:
Jonathan W Lischalk.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.